Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19

References

• COVID-19 Map—Johns Hopkins Coronavirus Resource Center. Johns Hopkins coronavirus resource center; 2020 [accessed 2022 Mar 25]. https://coronavirus.jhu.edu/map.html.
   Google Scholar
• World Health Organization. Coronavirus disease (COVID-19). Situation Report – 136; 2020 Jun. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200604-covid-19-sitrep-136.pdf?sfvrsn=fd36550b_2.
   Google Scholar
• The situation with the coronavirus; [accessed 2022 Mar 25]. https://www.coronavirus2020.kz/.
   Google Scholar
• Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):1–14. doi: 10.4014/jmb.2003.03011.
   PubMed Web of Science ®Google Scholar
• Li H, Liu SM, Yu ZH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951. doi: 10.1016/j.ijantimicag.2020.105951.
   PubMed Web of Science ®Google Scholar
• Lamb YN. Bnt162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81(4):495–501. doi: 10.1007/s40265-021-01480-7.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zeng J, Yan J. COVID-19 mRNA vaccines. J Genet Genomics. 2021;48(2):107–114. doi: 10.1016/j.jgg.2021.02.006.
   PubMed Web of Science ®Google Scholar
• Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021;17(6):1446–1460. doi: 10.7150/ijbs.59233.
   PubMed Web of Science ®Google Scholar
• Sagili ADP, Sivakumar K, Venugopal P, Sriram DK, George M. Can mRNA vaccines turn the tables during the COVID-19 pandemic? Current status and challenges. Clin Drug Investig. 2021;41(6):499–509. doi: 10.1007/s40261-021-01022-9.
   PubMed Web of Science ®Google Scholar
• Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, et al. A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against middle east respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301): 301-132. doi: 10.1126/scitranslmed.aac7462.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–1119. doi: 10.1016/S1473-3099(21)00127-4.
   PubMed Web of Science ®Google Scholar
• Liang JG, Su D, Song TZ, Zeng Y, Huang W, Wu J, Xu R, Luo P, Yang X, Zhang X, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021;12(1):1346. doi: 10.1038/s41467-021-21634-1.
   PubMed Web of Science ®Google Scholar
• Arashkia A, Jalilvand S, Mohajel N, Afchangi A, Azadmanesh K, Salehi-Vaziri M, Fazlalipour M, Pouriayevali MH, Jalali T, Mousavi Nasab SD, et al. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: state of the art and future prospects. Rev Med Virol. 2021;31(3):e2183. doi: 10.1002/rmv.2183.
   PubMed Web of Science ®Google Scholar
• Royal JM, Simpson CA, McCormick AA, Phillips A, Hume S, Morton J, Shepherd J, Oh Y, Swope K, DeBeauchamp JL, et al. Development of a SARS-CoV-2 vaccine candidate using plant-based manufacturing and a Tobacco mosaic virus-like nano-particle. Vaccines (Basel). 2021;9(11):1347. doi: 10.3390/vaccines9111347.
   PubMed Web of Science ®Google Scholar
• Akova M, Unal S. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):276. doi: 10.1186/s13063-021-05180-1.
   PubMedGoogle Scholar
• Mohandas S, Yadav PD, Shete-Aich A, Abraham P, Vadrevu KM, Sapkal G, Mote C, Nyayanit D, Gupta N, Srinivas VK, et al. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience. 2021;24(2):102054. doi: 10.1016/j.isci.2021.102054.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang C, Song Y, Coleman JR, Stawowczyk M, Tafrova J, Tasker S, Boltz D, Baker R, Garcia L, et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc Natl Acad Sci USA. 2021;118(29):e2102775118. doi: 10.1073/pnas.2102775118.
   PubMed Web of Science ®Google Scholar
• Sanchez-Felipe L, Vercruysse T, Sharma S, Ma J, Lemmens V, Van Looveren D, Arkalagud Javarappa MP, Boudewijns R, Malengier-Devlies B, Liesenborghs L, et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature. 2021;590(7845):320–325. doi: 10.1038/s41586-020-3035-9.
   PubMed Web of Science ®Google Scholar
• Munster VJ, Wells D, Lambe T, Wright D, Fischer RJ, Bushmaker T, Saturday G, van Doremalen N, Gilbert SC, de Wit E, et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines. 2017;2(1):28. doi: 10.1038/s41541-017-0029-1.
   PubMedGoogle Scholar
• Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S a. 2004;101(17):6641–6646. doi: 10.1073/pnas.0401939101.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang G, Li J, Nie Y, Shi X, Lian G, Wang W, Yin X, Zhao Y, Qu X, et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol. 2004;78(13):6938–6945. doi: 10.1128/JVI.78.13.6938-6945.2004.
   PubMed Web of Science ®Google Scholar
• Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang M-C, Viscidi R, Tsai Y-C, He L, Chen P-J, et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol. 2004;78(9):4638–4645. doi: 10.1128/JVI.78.9.4638-4645.2004.
   PubMed Web of Science ®Google Scholar
• Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ, van Kuppeveld FJM. The receptor binding domain of the new middle east respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol. 2013;87(16):9379–9383. doi: 10.1128/JVI.01277-13.
   PubMed Web of Science ®Google Scholar
• Nyon MP, Du L, Tseng CK, Seid CA, Pollet J, Naceanceno KS, Agrawal A, Algaissi A, Peng BH, Tai W, et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018;36(14):1853–1862. doi: 10.1016/j.vaccine.2018.02.065.
   PubMed Web of Science ®Google Scholar
• Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H, Cheng X, Wang C, Chang G, Zhu Q, et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 2004;23(6):391–394. doi: 10.1089/104454904323145272.
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77–81. doi: 10.1126/science.abc1932.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–721. doi: 10.1016/j.cell.2020.06.008.
   PubMed Web of Science ®Google Scholar
• The Minister of Healthcare of the Republic of Kazakhstan. Good Laboratory Practice (GLP) requirements of the republic of Kazakhstan; 2020 [accessed 2022 May 20]. https://adilet.zan.kz/eng/docs/V2000021596
   Google Scholar
• Roberts A, Lamirande EW, Vogel L, Baras B, Goossens G, Knott I, Chen J, Ward JM, Vassilev V, Subbarao K. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol. 2010;23(5):509–519. doi: 10.1089/vim.2010.0028.
   PubMed Web of Science ®Google Scholar
• Ricardo P, Elizabeth GP, de Roberta OP, Monica TRPC, Ana PB, Gang Z, Qianqian X, Esper GK, Jorge F, Christian FO, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:853.
   PubMed Web of Science ®Google Scholar
• Tabynov K, Kydyrbayev Z, Sansyzbay A, Khairullin B, Ryskeldinova S, Assanzhanova N, Kozhamkulov Y, Inkarbekov D. Immunogenic and protective properties of the first Kazakhstan vaccine against pandemic influenza a (H1N1) pdm09 in Ferrets. Virol Sin. 2012;27(6):344–351. doi: 10.1007/s12250-012-3272-7.
   Google Scholar
• Nurpeisova A, Kassenov M, Rametov N, Tabynov K, Renukaradhya GJ, Volgin Y, Sagymbay A, Makbuz A, Sansyzbay A, Khairullin B. Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine. Arch Virol. 2019;164(4):1027–1036. doi: 10.1007/s00705-019-04147-7.
   PubMed Web of Science ®Google Scholar
• Kumar R, Lee MH, Mickael C, Kassa B, Pasha Q, Tuder R, Graham B. Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. ERJ Open Res. 2020;6(4):00405–2020. doi: 10.1183/23120541.00405-2020.
   PubMedGoogle Scholar
• Tabynov K, Turebekov N, Babayeva M, Fomin G, Yerubayev T, Yespolov T, Li L, Gourapura JR, Petrovsky N, Tabynov K. An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. NPJ Vaccines. 2022;7(1):24. doi: 10.1038/s41541-022-00450-8.
   PubMed Web of Science ®Google Scholar
• Zhugunissov K, Zakarya K, Khairullin B, Orynbayev M, Abduraimov Y, Kassenov M, Sultankulova K, Kerimbayev A, Nurabayev S, Myrzakhmetova B, et al. Development of the inactivated QazCovid-in vaccine: protective efficacy of the vaccine in Syrian hamsters. Front Microbiol. 2021;12:720437. doi: 10.3389/fmicb.2021.720437.
   PubMed Web of Science ®Google Scholar
• Zakarya K, Kutumbetov L, Orynbayev M, Ye A, Sultankulova K, Kassenov M, Sarsenbayeva G, Kulmagambetov I, Davlyatshin T, Sergeeva M, et al. Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: a single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine. 2021;39:101078. doi: 10.1016/j.eclinm.2021.101078.
   PubMedGoogle Scholar
• The Minister of Healthcare of the Republic of Kazakhstan. Rules for conducting preclinical (non-clinical) studies, clinical trials; 2018 [accessed 2022 May 20]. https://adilet.zan.kz/rus/docs/V1800016768
   Google Scholar
• Delwatta SL, Gunatilake M, Baumans V, Seneviratne MD, Dissanayaka MLB, Batagoda SS, Udagedara AH, Prasad BW. Reference values for selected hematological, biochemical and physiological parameters of Sprague-Dawley rats at the animal house, faculty of medicine, University of Colombo, Sri Lanka. Animal Model Exp Med. 2018;1(4):250–254. doi: 10.1002/ame2.12041.
   PubMedGoogle Scholar
• Sharma S, Varsha KK, Kumari S, Gopalakrishnan V, Jose AE, Choudhary B, Mantelingu K, Raghavan SC. Acute toxicity analysis of Disarib, an inhibitor of BCL2. Sci Rep. 2020;10(1):15188. doi: 10.1038/s41598-020-72058-8.
   PubMed Web of Science ®Google Scholar
• Sireeratawong S, Jaijoy K, Khonsung P, Lertprasertsuk N, Ingkaninan K. Acute and chronic toxicities of Bacopa monnieri extract in Sprague-Dawley rats. BMC Complement Altern Med. 2016;16(1):249. doi: 10.1186/s12906-016-1236-4.
   PubMed Web of Science ®Google Scholar
• López Y, Infante JF, Sifontes S, Díaz D, Pérez V, Año G, Hernández T, Fernández S, Castaño JL, Cedré B, et al. Pharmacology and toxicology of an oral tablet whole cells inactivated cholera vaccine in Sprague Dawley rats. Vaccine. 2011;29(19):3596–3599. doi: 10.1016/j.vaccine.2011.02.074.
   PubMed Web of Science ®Google Scholar
• Reynaldo O, Fraleigh NL, Lewicky JD, Fariñas M, Hernández T, Martel AL, Navarro I, Dagmar G-R, Acevedo R, Hoang-Thanh L. Repeat-Dose toxicity study using the AFPL1-conjugate nicotine vaccine in male Sprague Dawley rats. Pharmaceutics. 2020;11:626.
   Web of Science ®Google Scholar
• Forster F. Study designs for the nonclinical safety testing of new vaccine products. J Pharmacol Toxicol. 2012;66(1):1–7. doi: 10.1016/j.vascn.2012.04.003.
   PubMed Web of Science ®Google Scholar
• Al-Humadi N. Pre-Clinical toxicology considerations for vaccine development. Vaccine. 2017;35(43):5762–5767. doi: 10.1016/j.vaccine.2017.09.021.
   PubMed Web of Science ®Google Scholar
• Kandeil A, Mostafa A, Hegazy RR, El-Shesheny R, Taweel EA, Gomaa MR, Shehata M, Elbaset MA, Kayed AE, Mahmoud SH, et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: preclinical studies. Vaccines (Basel). 2021;9(3):214. doi: 10.3390/vaccines9030214.
   PubMed Web of Science ®Google Scholar
• Chan J-W, Zhang AJ, Yuan S, Poon V-M, Chan C-S, Lee A-Y, W-M C, Fan Z, H-W T, Wen L, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020;71(16):2428–2446. doi: 10.1093/cid/ciaa644.
   PubMedGoogle Scholar
• Sia SF, Yan LM, Chin AWH, Fung K, Choy KT, Wong AYL, Kaewpreedee P, Perera RAPM, Poon LLM, Nicholls JM, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583(7818):834–838. doi: 10.1038/s41586-020-2342-5.
   PubMed Web of Science ®Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020;117(28):16587–16595. doi: 10.1073/pnas.2009799117.
   PubMed Web of Science ®Google Scholar